Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection

Rina Rosalia Department of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University – Dubai Campus, Dubai, United Arab EmiratesCorrespondence: Rina RosaliaDepartment of Health Sciences, College of Science, Health, Engineering and Education (SHEE), M...

Full description

Bibliographic Details
Main Author: Rosalia R
Format: Article
Language:English
Published: Dove Medical Press 2021-01-01
Series:Drug, Healthcare and Patient Safety
Subjects:
Online Access:https://www.dovepress.com/perspectives-on-repurposed-drugs-based-on-globally-accepted-therapeuti-peer-reviewed-article-DHPS
id doaj-2581d3382b6547ccb188f15fee10d6e4
record_format Article
spelling doaj-2581d3382b6547ccb188f15fee10d6e42021-01-28T20:09:25ZengDove Medical PressDrug, Healthcare and Patient Safety1179-13652021-01-01Volume 13111861540Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 InfectionRosalia RRina Rosalia Department of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University – Dubai Campus, Dubai, United Arab EmiratesCorrespondence: Rina RosaliaDepartment of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University – Dubai Campus, Level 1, Block 18, Dubai Knowledge Park, Dubai 345001, United Arab EmiratesTel +971 4 4355700Fax +971 4 4355704Email rina.rosalia@murdoch.edu.auAbstract: A beta coronavirus was identified in Wuhan, China, in December 2019 and was named severe acute respiratory syndrome coronavirus-2. It spread globally at a rapid rate and killed innumerable people. The SARS-CoV-2 infection, also called coronavirus disease 2019, was declared a pandemic by WHO on March 11, 2020. The increasing number of SARS-CoV-2 related deaths is due to a number of reasons. A few antiviral, antimicrobial, and immune-based drugs have been repurposed for treatment as well as improvement of patient prognosis. These drugs are currently being studied in clinical trials conducted by the World Health Organization (WHO), National Institutes of Health (NIH), and other global health organizations to identify the agents that produce maximum positive patient outcomes and reduction in mortality rate. The aim of this article is to discuss the safety and efficacy of the repurposed drugs in SARS-CoV-2 infection based on currently available clinical evidence and to emphasize the importance of caution required whilst employing the international therapeutic guidelines. Also highlighted in this article are certain specific comorbid conditions, that either involve treatment with the repurposed drugs or have a direct impact of the virus in patients owing to their vulnerability.Keywords: MERS, SARS-CoV-2, acute respiratory distress syndrome, cytokine storm syndrome, therapeutic guidelines, COVID-19https://www.dovepress.com/perspectives-on-repurposed-drugs-based-on-globally-accepted-therapeuti-peer-reviewed-article-DHPSmerssars-cov-2acute respiratory distress syndromecytokine storm syndrometherapeutic guidelinescovid-19
collection DOAJ
language English
format Article
sources DOAJ
author Rosalia R
spellingShingle Rosalia R
Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
Drug, Healthcare and Patient Safety
mers
sars-cov-2
acute respiratory distress syndrome
cytokine storm syndrome
therapeutic guidelines
covid-19
author_facet Rosalia R
author_sort Rosalia R
title Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
title_short Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
title_full Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
title_fullStr Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
title_full_unstemmed Perspectives on Repurposed Drugs Based on Globally Accepted Therapeutic Guidelines to Combat SARS-CoV-2 Infection
title_sort perspectives on repurposed drugs based on globally accepted therapeutic guidelines to combat sars-cov-2 infection
publisher Dove Medical Press
series Drug, Healthcare and Patient Safety
issn 1179-1365
publishDate 2021-01-01
description Rina Rosalia Department of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University – Dubai Campus, Dubai, United Arab EmiratesCorrespondence: Rina RosaliaDepartment of Health Sciences, College of Science, Health, Engineering and Education (SHEE), Murdoch University – Dubai Campus, Level 1, Block 18, Dubai Knowledge Park, Dubai 345001, United Arab EmiratesTel +971 4 4355700Fax +971 4 4355704Email rina.rosalia@murdoch.edu.auAbstract: A beta coronavirus was identified in Wuhan, China, in December 2019 and was named severe acute respiratory syndrome coronavirus-2. It spread globally at a rapid rate and killed innumerable people. The SARS-CoV-2 infection, also called coronavirus disease 2019, was declared a pandemic by WHO on March 11, 2020. The increasing number of SARS-CoV-2 related deaths is due to a number of reasons. A few antiviral, antimicrobial, and immune-based drugs have been repurposed for treatment as well as improvement of patient prognosis. These drugs are currently being studied in clinical trials conducted by the World Health Organization (WHO), National Institutes of Health (NIH), and other global health organizations to identify the agents that produce maximum positive patient outcomes and reduction in mortality rate. The aim of this article is to discuss the safety and efficacy of the repurposed drugs in SARS-CoV-2 infection based on currently available clinical evidence and to emphasize the importance of caution required whilst employing the international therapeutic guidelines. Also highlighted in this article are certain specific comorbid conditions, that either involve treatment with the repurposed drugs or have a direct impact of the virus in patients owing to their vulnerability.Keywords: MERS, SARS-CoV-2, acute respiratory distress syndrome, cytokine storm syndrome, therapeutic guidelines, COVID-19
topic mers
sars-cov-2
acute respiratory distress syndrome
cytokine storm syndrome
therapeutic guidelines
covid-19
url https://www.dovepress.com/perspectives-on-repurposed-drugs-based-on-globally-accepted-therapeuti-peer-reviewed-article-DHPS
work_keys_str_mv AT rosaliar perspectivesonrepurposeddrugsbasedongloballyacceptedtherapeuticguidelinestocombatsarscov2infection
_version_ 1724319484296036352